ReviewFrontiers in microbiology2026
Diagnostic value and challenges in the immune regulation of pentraxin 3 in infectious diseases.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pentraxin-3 in thyroid nodules: a systemic marker of pathology and a local mediator of inflammation and carcinoma.Frontiers in endocrinology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious diseases pose a severe threat to human health, and their early and precise diagnosis and intervention remain a major challenge in clinical practice. This review systematically examines the diagnostic value and immunomodulatory role of PTX3 across a spectrum of infectious diseases, including those affecting the respiratory, cardiovascular, digestive, urinary, and nervous systems, as well as orthopedic and skin infections. The aim is to provide novel perspectives for overcoming the bottleneck in precise diagnosis and treatment of infectious diseases. Currently, diagnosis and assessment primarily rely on clinical manifestations, conventional inflammatory markers such as C-reactive protein (CRP) and procalcitonin, and pathogen detection. However, these methods often have limitations in sensitivity, specificity, and early warning capability, underscoring the need for novel, high-value biomarkers to enhance diagnostic and therapeutic precision. Long pentraxin 3 (PTX3), a key acute-phase reactant protein and soluble pattern recognition receptor (PRR), has recently garnered considerable attention for its role in infectious diseases. PTX3 is rapidly synthesized by innate immune and endothelial cells in response to stimulation by pathogens or inflammatory mediators. Functionally, PTX3 contributes to host defense through opsonophagocytosis, complement activation, and modulation of inflammatory responses. Quantification of circulating PTX3 levels demonstrates potential as an adjunctive biomarker for the diagnosis of infectious diseases and holds considerable value in early risk stratification, precise disease assessment, and personalized therapeutic strategies. Nevertheless, the clinical application of PTX3 faces two major challenges in immune regulation. Its broad-spectrum responsiveness to inflammation limits its specificity in pathogen differentiation, and the mechanisms underlying its immunomodulatory activity remain complex. This review systematically summarizes recent advances in the diagnostic significance and immunoregulatory mechanisms of PTX3, providing new insights into overcoming current challenges in the precision diagnosis and treatment of infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.